Stockscreener 앱 받기
0.8899
1.01%
0.0187
전일 마감가:
$0.8712
열려 있는:
$0.8876
하루 거래량:
304.72K
Relative Volume:
0.14
시가총액:
$60.46M
수익:
$3.67M
순이익/손실:
$-13.83M
주가수익비율:
-3.1782
EPS:
-0.28
순현금흐름:
$-10.79M
1주 성능:
-12.00%
1개월 성능:
-10.71%
6개월 성능:
-21.78%
1년 성능:
+56.00%
1일 변동 폭
$0.8641
$0.8976
1주일 범위
$0.8641
$1.01
52주 변동 폭
$0.5101
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
ICCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.88 | 60.07M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
131.90 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.86 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
366.38 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.28 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.26 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
Can a trend reversal in IceCure Medical Ltd lead to recoveryJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
What momentum indicators show for IceCure Medical Ltd stock2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Pattern recognition hints at IceCure Medical Ltd upsideNew Guidance & Free Accurate Trade Setup Notifications - newser.com
New FDA-Approved Breast Cancer Treatment Freezes Tumors Instead Of Removing Them - essence.com
Brookline Capital Management Predicts IceCure Medical Q3 Earnings - MarketBeat
IceCure Medical to Attend the 2025 Maxim Growth Summit - WV News
IceCure Medical (NASDAQ:ICCM) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
IceCure Medical : Company Presentation - MarketScreener
FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women - Medical Dialogues
IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50 - MarketBeat
HC Wainwright & Co. Maintains IceCure Medical (ICCM) Buy Recommendation - Nasdaq
IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright - Investing.com
IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright - TipRanks
ICCM: HC Wainwright & Co. Boosts Price Target to $2.50, Maintains Buy Rating | ICCM Stock News - GuruFocus
IceCure ProSense Cryoablation Receives FDA Marketing Authorization for Treating Low-Risk Breast Cancer in Women Aged 70+ - Imaging Technology News
Icecure gets FDA nod for Prosense cryoablation in breast cancer - BioWorld MedTech
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Yahoo Finance
Transcript : IceCure Medical LtdSpecial Call - MarketScreener
What MACD and RSI say about IceCure Medical Ltd2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for IceCure Medical LtdJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
IceCure Medical Ltd’s volatility index tracking explained2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
IceCure Medical Ltd stock prediction for this weekMarket Performance Recap & Reliable Breakout Forecasts - newser.com
What drives EcoSynthetix Inc 0Y8 stock priceStock Split Announcements & Rapid Wealth Building Tips - earlytimes.in
IceCure Medical Ltd Stock Analysis and ForecastPrice-to-Book Ratio Updates & Your Free Entry to Smart Investing Starts Here - earlytimes.in
IceCure Receives FDA Marketing Authorization for ProSense(R) Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
Using portfolio simulators with IceCure Medical Ltd includedJuly 2025 Retail & Safe Capital Investment Plans - newser.com
Key metrics from IceCure Medical Ltd’s quarterly dataQuarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Developing predictive dashboards with IceCure Medical Ltd data2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Is IceCure Medical Ltd stock attractive for growth ETFsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 49.8% in September - MarketBeat
IceCure Medical Surges on FDA Authorization for Breast Cancer Treatment - StocksToTrade
IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of "Buy" from Analysts - MarketBeat
IceCure Medical Ltd. Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
FDA approves IceCure cryoablation for breast cancer - MassDevice
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - Lelezard
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - Lelezard
ICCM Gains FDA Approval for ProSense Cryoablation System in Cert - GuruFocus
IceCure Receives FDA Marketing Authorization for ProSense® Cryoa - GuruFocus
Icecure Medical stock surges after FDA approves breast cancer treatment - Investing.com
IceCure Medical Gets FDA Approval for ProSense Breast Cancer Treatment; Shares Rise - MarketScreener
IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation - TipRanks
Full technical analysis of IceCure Medical Ltd stock2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
46,000 U.S. Women: IceCure Receives FDA Marketing Authorization for ProSense®; CPT III Covers $3,800 - Stock Titan
Detecting price anomalies in IceCure Medical Ltd with AILong Setup & Low Risk High Win Rate Picks - newser.com
Visualizing IceCure Medical Ltd stock with heatmapsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Icecure's Prosense At the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer - MarketScreener
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - Barchart.com
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.29%
자본화:
|
볼륨(24시간):